Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.

被引：0
|
作者：
Ni, Jun
Zhang, Xiaotong
Pan, Ruili
Wang, Hanping
Si, Xiaoyan
Cui, Xiaoxia
Zhang, Li
机构：
[1] Chinese Acad Med Sci Peking Union Med Coll, Peking Union Med Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China
[2] Peking Union Med Coll & Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Peking Union Med Coll Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Resp Med, Peking Union Med Coll Hosp, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll & Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Peking Union Med Coll Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8573
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study
    Wu, L.
    Pu, X.
    Chen, B.
    Wang, Q.
    Liu, L.
    Li, K.
    Kong, Y.
    Xu, F.
    Li, J.
    Xu, L.
    Tang, Y.
    Xu, Y.
    Xiao, M.
    Liu, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1075 - S1076
  • [32] RETRACTED: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer (Retracted Article)
    Ye, Wei
    Song, Zhonghua
    Lin, Zhongkun
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [33] The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer
    Fu, Jun
    Fang, Sanyou
    Wen, Yin
    Wang, Yanbing
    Yin, Xin
    Wang, Daofeng
    JOURNAL OF BUON, 2020, 25 (04): : 1707 - 1713
  • [34] Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
    Qiao, Liu
    Zhou, Zhen
    Zeng, Xiaohui
    Tan, Chongqing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [35] Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
    Mo, Yunyan
    Pan, Yufei
    Zhang, Bin
    Zhang, Jian
    Su, Yixin
    Liu, Zhengchun
    Luo, Meiqing
    Qin, Guanjie
    Kong, Xiangyun
    Zhang, Rongjun
    Pan, Yu
    Liang, Yi
    Wang, Defeng
    Wei, Yuejia
    Chen, Hengwei
    Jiang, Wei
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [36] Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
    Gu, Yinfang
    Zou, Xiaofang
    Zhu, Junlin
    Wu, Guowu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)
  • [37] A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
    Wu, L.
    Pu, X.
    Lin, G.
    Xiao, M.
    Lin, J.
    Wang, Q.
    Kong, Y.
    Yan, X.
    Xu, F.
    Xu, Y.
    Li, J.
    Li, K.
    Chen, B.
    Wen, X.
    Tan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S387 - S387
  • [38] Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial
    Liu, Ming
    Qiu, Guihuan
    Guan, Wenhui
    Xie, Xiaohong
    Lin, Xinqing
    Xie, Zhanhong
    Zhang, Jiexia
    Qin, Yinyin
    Du, Haijian
    Chen, Xin
    Deng, Yu
    Li, Shiyue
    Zhong, Nanshan
    Zhou, Chengzhi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [39] Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.
    Xu, Yaping
    Ni, Jian
    Ren, Shengxiang
    Xu, Xiaoling
    Hu, Min
    Xu, Qinghua
    Chen, Yun
    Zhu, Yaoyao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)
    Lu, Y.
    Zhang, D.
    Zhang, Y.
    Liu, F.
    Wang, Z.
    Wang, F.
    Li, Y.
    Wang, F.
    Luo, H. Y.
    Guo, G.
    Qiu, M.
    Wang, D.
    Chen, D.
    Jin, Y.
    Liu, Y.
    Chen, J.
    Xu, R-H
    ANNALS OF ONCOLOGY, 2024, 35 : S231 - S231
12345